IP Verse

Crystalline Forms Of N-(4-(4-(Cyclopropylmethyl) Piperazine-1-Carbonyl)Phenyl)Quinoline-8-Sulfonamide - EP3713919

The patent EP3713919 was granted to Agios Pharmaceuticals on Aug 2, 2023. The application was originally filed on Nov 21, 2018 under application number EP18821779A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3713919

AGIOS PHARMACEUTICALS
Application Number
EP18821779A
Filing Date
Nov 21, 2018
Status
Granted And Under Opposition
Jun 30, 2023
Grant Date
Aug 2, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOTTI & FERRARIMay 2, 2024BOTTI & FERRARIADMISSIBLE
SANDOZMay 2, 2024TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2011002817
DESCRIPTIONWO2016201227
INTERNATIONAL-SEARCH-REPORTUS8785450
INTERNATIONAL-SEARCH-REPORTWO2016201227
OPPOSITIONEP3307271
OPPOSITIONUS8785450
OPPOSITIONWO2012151451
OPPOSITIONWO2016201227

Non-Patent Literature (NPL) Citations (39) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CANU, Blood Cells, Molecules and Diseases, (20160000), vol. 57, pages 100 - 109-
DESCRIPTION- CANU., "Molecules and Diseases", Blood Cells, (20160000), vol. 57, pages 100 - 109-
DESCRIPTION- WIJK et al., Human Mutation, (20080000), vol. 30, no. 3, pages 446 - 453-
EXAMINATION- Aungst: "Optimising Oral Bioavailability of Pharmaceutical Leads" Drug Development, 2006, 84-86.-
EXAMINATION- Fink et al.: "Evaluating the Role of Solubility in Oral Absorption of Poorly Water-Soluble Drugs Using Physiologically-Based Pharmacokinetic Modelling", Clinical Pharmacology & Therapeutics 2020, 107, 650-661.-
INTERNATIONAL-SEARCH-REPORT- HARWOOD; MOODY, Experimental organic chemistry - Principles and practice, Blackwell Science, (19890101), pages 127 - 132, ISBN 978-0-632-02016-4, XP003025361 [L] 1-24,42 * Pages 127-132, chapter: "Crystallization". Cited as common general knowledge. *-
INTERNATIONAL-SEARCH-REPORT- IMSRESEARCH, IQVIA, LONDON, UK, (20181213), Database accession no. 2014:8, XP002788334 [T] 1-42 * abstract *-
INTERNATIONAL-SEARCH-REPORT- REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (20171205), Database accession no. 2151847-10-6, XP002788333 [AP] 1-42 * abstract *-
INTERNATIONAL-SEARCH-REPORT- STAHL ET AL., Pharmaceutical Salts: Properties, Selections, and Use, passages, HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION, AND USE, ZÜRICH : VERL. HELVETICA CHIMICA ACTA ; WEINHEIM [U.A.] : WILEY-VCH, DE, PAGE(S) 212-214,254,305, (20020101), pages 212-214, 254, 305 - 306, ISBN 978-3-906390-26-0, XP002550486 [L] 1-20,23-42 * Page 212, section 8.1.2; page 306: sulfuric acid. Cited as common general knowledge. *-
INTERNATIONAL-SEARCH-REPORT- BERGE ET AL., "PHARMACEUTICALS SALTS", JOURNAL OF PHARMACEUTICAL SCIENCES, (19770101), vol. 66, no. 1, doi:10.1002/JPS.2600660104, ISSN 0022-3549, pages 1 - 19, XP000562636 [L] 1-20,23-42 * Page 1, paragraph bridging left and right columns; page 2, table 1. *
INTERNATIONAL-SEARCH-REPORT- CAIRA, "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, (19980101), vol. 198, ISSN 0340-1022, pages 163 - 208, XP008166276 [L] 1-26 * Paragraph bridging pages 165 and 166. Cited as common general knowledge. *
INTERNATIONAL-SEARCH-REPORT- "Chapter 11, Tools for Purifying the Product: Column Chromatography, Crystallization and Reslurrying", Anderson, Practical Process Research & Development, San Diego, Academic Press, (20000101), pages 223 - 224, ISBN 978-0-12-059475-7, XP002565895 [L] 1-24,42 * Paragraph bridging pages 223-224. Cited as common general knowledge. *
INTERNATIONAL-SEARCH-REPORT- HANCOCK; ZOGRAFI, "Characteristics and Significance of the Amorphous State in Pharmaceutical Systems", JOURNAL OF PHARMACEUTICAL SCIENCES, (19970101), vol. 86, no. 1, doi:10.1021/js9601896, pages 1 - 12, XP055274556 [L] 25-40 * Page 1, abstract; page 1, left column and figure 1. Cited as common general knowledge. *
INTERNATIONAL-SEARCH-REPORT- BYRN ET AL., "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", PHARMACEUTICAL RESEARCH, (19950101), vol. 12, no. 7, doi:10.1023/A:1016241927429, pages 945 - 954, XP055531015 [L] 1-26 * Abstract; page 945, lwft column paragraph 1 to right column, paragraph 1; page 946, figure 1 and right column, paragraphs 2-3; page 949, figure 6 and left column, paragraph 2; page 952, figure 11 and left column, paragraph 2. Cited as common general knowledge. *
OPPOSITION- Alfonso R Gennaro, Nicholas G Popovich, Aro H Der Marderosian, Roger L Schaare, Glen R Hanson, Joseph B Schwarz, Thomas Medwick An H Steve White, "Passage; Chapter 38. Preformulation", Remington: The Science and Practice of Pharmacy Twentieth edition, (20000101), pages 704 - 707, ISBN 978-0-7817-5025-7, XP055586701-
OPPOSITION- Anonymous, "2.9.33. - Characterisation of Crystalline and Partially Crystalline Solids by X-Ray Powder Diffraction (XRPD)", European Pharmacopeia 7.0, (20090101), pages 301 - 305, XP055582946-
OPPOSITION- Anonymous, "8-Quinolinesulfonamide, N-[4-[[4-(cyclopropylmethyl)-1- piperazinyl]carbonyl]phenyl]-, sulfate, hydrate (2:1:3) ", REGISTRY, (20171205), Database accession no. 2151847-10-6, XP093189738-
OPPOSITION- Aulton Michael E., "Passage; Preformulation", Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins , (20000101), pages 703 - 706, ISBN 978-0-683-30647-7, XP093189732-
OPPOSITION- Bauer K.H. Et Al., "Passage; Kapitel 7 - Biopharmazie", Lehrbuch der Pharmazeutischen Technologie- Mit einer Einführung in die Biopharmazie, Wissenschaftliche Verslagsgesellschaft mbH, Stuttgart , (20060101), pages 214 - 217, ISBN 3-8047-2222-9, XP055436785-
OPPOSITION- Bavin Mike , "Polymorphism in Process Development", Chemistry & Industry, (19890821), pages 527 - 529, XP093192606-
OPPOSITION- Bertram G. Katzung, "Chapter 1 Introduction", Bertram G. Katzung, Bertram G. Katzung et al., Basic & Clinical Pharmacology, US, McGraw-Hill Medical, (20120101), pages 1 - 13, ISBN 978-0-07-176402-5, XP009555923-
OPPOSITION- D29 - EPO Board of Appeal decision T1418/22 dated 19th November 2024-
OPPOSITION- D30 - T1061/16-
OPPOSITION- Dhaliwal Gurpreet, Patricia A. Cornett, Lawrence M. Tierney, Jr., "Hemolytic Anemia", AMERICAN FAMILY PHYSICIAN, American Academy of Family Physicians, US, US , (20040601), vol. 69, no. 11, ISSN 0002-838X, pages 2599 - 2607, XP093189719-
OPPOSITION- James Wells, "Chapter 8: Pharmaceutical preformulation: the physicochemical properties of drug substances.", PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, Elsevier , (20020101), pages 113 - 138, ISBN 0-443-05517-3, XP009555452-
OPPOSITION- James Wells, "Passage; Chapter Biopharmaceutical Principles of Drug Delivery", PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, Elsevier , (20020101), pages 236 - 239, ISBN 0-443-05517-3, XP009555934-
OPPOSITION- Maria Almira Correia, "Chapter 4: Drug Biotransformation", Maria Almira Correia, BERTRAM G. KATZUNG ET AL., Basic & Clinical Pharmacology, US, McGraw-Hill Medical, (20120101), pages 53 - 68, ISBN 978-0-07-176402-5, XP009555926-
OPPOSITION- M. Ashford, "22 Assessment of biopharmaceutical properties", Aulton's pharmaceutics: the design and manufacture of medicines, 3rd edition. , (20070101), pages 304 - 323, ISBN 0443101086, XP009561233-
OPPOSITION- Nicholas H. G. Holford, "Chapter 3: Pharmacokinetics & Pharmacodynamics: Rational Dosing & the Time Course of Drug Actio", Nicholas H. G. Holford, BERTRAM G. KATZUNG ET AL., Basic & Clinical Pharmacology, US, McGraw-Hill Medical, (20120101), pages 37 - 51, ISBN 978-0-07-176402-5, XP009555925-
OPPOSITION- Sisir Bhattacharya, Harry G. Brittain, Raj Suryanarayanan, "Chapter 9: Thermoanalytical and Crystallographic Methods", Polymorphism in Pharmaceutical solids ED. 2, US, INFORMA HEALTHCARE , (20090727), pages 319 - 346, ISBN 0-8247-0237-9, XP009555933-
OPPOSITION- von Zastrow, Mark, "Chapter 2: Drug Receptors / Pharmacodynamics", von Zastrow, Mark, BERTRAM G. KATZUNG ET AL., Basic & Clinical Pharmacology, US, McGraw-Hill Medical, (20120101), pages 15 - 35, ISBN 978-0-07-176401-8, XP009555924-
OPPOSITION- BERGE S. M., BIGHLEY L. D., MONKHOUSE D. C., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, Wiley, United States, United States, (19770101), vol. 66., no. 01., doi:10.1002/jps.2600660104, ISSN 0022-3549, pages 01 - 19., XP000562636
OPPOSITION- Alfons Grunenberg, "Polymorphie und Thermische Analyse pharmazeutischer Wirkstoffe", Pharmazie in unserer Zeit, (19970101), vol. 26, no. 5, doi:10.1002/pauz.19970260506, pages 224 - 231, XP055745450
OPPOSITION- Mino R. Caira, "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY., SPRINGER, BERLIN., DE, DE , (19980101), vol. 198, doi:10.1007/3-540-69178-2_5, ISSN 0340-1022, pages 163 - 208, XP008166276
OPPOSITION- Arthur J. Atkinson et al., "Chapter 4: Drug Absorption and Bioavailability", Principles of Clinical Pharmacology, NL, USA, Academic Press, (20061019), pages 37 - 49, doi:10.1016/B978-012369417-1/50044-4, ISBN 978-0-12-369417-1, XP009555930
OPPOSITION- Lydie Da Costa, Julie Galimand, Odile Fenneteau, Narla Mohandas, "Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders", Blood Reviews, Churchill Livingstone, (20130701), vol. 27, no. 4, doi:10.1016/j.blre.2013.04.003, ISSN 0268960X, pages 167 - 178, XP055092704
OPPOSITION- Elder David P.; Holm René; Diego Heidi Lopez de , "Use of pharmaceutical salts and cocrystals to address the issue of poor solubility", International Journal of Pharmaceutics, ELSEVIER, NL, NL , (20121124), vol. 453, no. 1, doi:10.1016/j.ijpharm.2012.11.028, ISSN 0378-5173, pages 88 - 100, XP028675213
OPPOSITION- Stephen Byrn, Ralph Pfeiffer, Michael Ganey, Charles Hoiberg and Guirag Poochikian, "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950701), vol. 12, no. 7, doi:10.1023/A:1016241927429, pages 945 - 954, XP055531015
OPPOSITION- Hans H Jung;Adrian Danek;Ruth H Walker, "Neuroacanthocytosis Syndromes", Orphanet Journal of Rare Diseases, BioMed Central Ltd, Lo, Lo , (20111025), vol. 6, no. 1, doi:10.1186/1750-1172-6-68, ISSN 1750-1172, page 68, XP021114232

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents